The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1410
ISSUE1410
February 18, 2013
Mirabegron (Myrbetriq) for Overactive Bladder
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Mirabegron (Myrbetriq) for Overactive Bladder
February 18, 2013 (Issue: 1410)
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH
trick] – Astellas), a beta-3 adrenergic agonist, has
been approved by the FDA for the treatment of overactive
bladder. It is the first beta-3 adrenergic agonist
to be approved for any indication...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.